0.00
100.00%
-40.50
시간 외 거래:
41.95
41.95
+
Citius Oncology Inc 주식(TENK)의 최신 뉴스
Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada
Civitas Resources started as Buy at J.P. Morgan ahead of likely strong buybacks - Seeking Alpha
Cytek Biosciences (NASDAQ:CTKB) Shares Down 2.6% - Defense World
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc (CTXR)’s Day in Review: Closing at 0.50, Down by -2.90 - The Dwinnex
The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News
Results from Cytek BioSciences Inc (CTKB) show potential - US Post News
Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News
M&A News: Citigroup (NYSE:C) Sells Trust Business to JTC for $80M - TipRanks
Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Telix's Phase 3 ZIRCON Trial Published in Lancet Oncology - Mirage News
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News
Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
Citius Oncology Inc. (CTOR) requires closer examination - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia
Citius Oncology Inc. completes strategic acquisition - Investing.com
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com UK
Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex
CTOR stock touches 52-week low at $3.20 amid market fluctuations - Investing.com
TenX Keane Acquisition (NASDAQ:TENKR) Sees Significant Growth in Short Interest - Defense World
Citius merges oncology subsidiary with TenX Keane - Yahoo Finance
Citius merges oncology subsidiary with TenX Keane - Pharmaceutical Technology
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz
TenX Keane Acquisition (NASDAQ:TENK) Short Interest Update - MarketBeat
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - Kilgore News Herald
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Kilgore News Herald
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com
TenX Keane Acquisition Addresses Trading Halt, Continues - GlobeNewswire
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - StockTitan
TenX Keane addresses trading halt, continues toward combination closing - TipRanks
New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online
US FDA approves Citius' therapy for rare blood cancer - Reuters.com
Citius Pharmaceuticals stock falls despite approval of its lymphoma drug - Kursiv Media
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals Advances Oncology Spinoff Through Merger with TenX Keane - Vancity Buzz
(TENK) Trading Advice - news.stocktradersdaily.com
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology - Nasdaq
TenX Keane Acquisition (TENK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Lymphoma drug developer Citius Pharma finalizing spin-off of oncology division - Kursiv Media
자본화:
|
볼륨(24시간):